We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Scynexis Europe is now Selcia Following Spin off from Scynexis Inc.

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Scynexis Europe is now Selcia Following Spin off from Scynexis Inc."

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

Scynexis, Inc. has sold its wholly-owned subsidiary in the United Kingdom, Scynexis Europe Limited, to its U.K. management. The new company will operate under the name Selcia Limited.

Dr. Hans Fliri, the Managing Director of Selcia said, "We are pleased to have this opportunity to develop our business as the only dedicated provider of custom radiolabeling, chemistry and analytics services to a worldwide customer base."

"The continuing rapid expansion of our business has provided us with the confidence to move forward as an independent company."

"We are already in the process of offering new services such as metabolomics and metabolic profiling, and their integration with chemistry."

Fliri continued, "Our service business is based on a track record of scientific excellence at the Ongar site and a skillful, highly committed staff."

"We plan to increase capacity in this business and to invest in new development programs in the future. This will create opportunities for new financial investment in the company."

"The transaction will allow Scynexis to concentrate on its core business and partners and will provide Selcia the opportunity to focus on its services," said Dr. Yves Ribeill, President and Chief Executive Officer of Scynexis, Inc.

"By doing so, Scynexis can enhance our growing presence in the global pharmaceutical marketplace and continue to build discovery collaborations with major companies."

Ribeill Added, "Scynexis extends its best wishes to Dr. Fliri and his highly qualified team."